Eledon Pharma Reports Improved Quality Of Life And Reduced Symptom Burden With Tegoprubart In Kidney Transplant Patients At ASN Kidney Week 2026
Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom
Share
Why It Matters
Eledon's kidney transplant medicine helped patients feel better. This positive result shows the drug might work well in real patients.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.